ACA
CRSP icon

Aptus Capital Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Aptus Capital Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$226K Buy
+4,141
New +$218K ﹤0.01% 1071
2026
Q1 		– Sell
-4,147
Closed -$217K – 1697
2025
Q4 		$217K Sell
4,147
-218
-5% -$13.1K ﹤0.01% 1005
2025
Q3 		$283K Sell
4,365
-3
-0.1% -$172 ﹤0.01% 861
2025
Q2 		$212K Buy
+4,368
New +$169K ﹤0.01% 928
2025
Q1 		– Sell
-6,298
Closed -$248K – 1446
2024
Q4 		$248K Buy
+6,298
New +$297K ﹤0.01% 825
2023
Q3 		– Sell
-4,175
Closed -$234K – 907
2023
Q2 		$234K Buy
+4,175
New +$237K 0.01% 455

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Aptus Capital Advisors's CRSP Position: Q2 2026 in Review

Aptus Capital Advisors opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 4,141 shares worth $226K. The stake represents ﹤0.01% of the portfolio and ranks #1071 among its holdings. This is a return to the name: Aptus Capital Advisors previously reported a position in CRSP as recently as Q4 2025.

Aptus Capital Advisors first reported a position in CRSP in Q2 2023 and has held it in 6 quarters since. The position peaked at $283K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Aptus Capital Advisors held 4,141 shares of CRISPR Therapeutics worth $226K as of Q2 2026.
  • CRISPR Therapeutics was a new Aptus Capital Advisors position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q2 2026, its #1071 holding.
  • Aptus Capital Advisors first reported a position in CRISPR Therapeutics in Q2 2023 and has held it in 6 quarters since.
  • Aptus Capital Advisors's CRISPR Therapeutics position peaked at $283K in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.